Fusion Antibodies plc (AIM: FAB)

Market Cap	8.78M
Revenue (ttm)	1.80M
Net Income (ttm)	-1.59M
Shares Out	95.95M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661,393
Average Volume	1,740,387
Open	9.34
Previous Close	9.10
Day's Range	8.70 - 9.50
52-Week Range	2.80 - 12.00
Beta	0.33
RSI	60.96
Earnings Date	Feb 18, 2025

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 27
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: FAB

Financial Performance

In 2023, Fusion Antibodies's revenue was 1.14 million, a decrease of -60.84% compared to the previous year's 2.90 million. Losses were -2.19 million, -15.64% less than in 2022.